In the adenocarcinoma group receiving PD-1/PD-L1 inhibitor treatment, the immunohistochemical expression of YTHDF1 was significantly negatively associated with CD4 expression (Supplementary Figure 1). The gene discussed is CD4; the disease is adenocarcinoma.